Payment & Shipping Terms:
51019 43 3,
764 01 2
CAS : 853029-57-9 Linagliptin Intermediate GMP condition
Chemical Name : 1 - [ ( 4 - Methylquinazolin - 2 - yl ) methyl ] - 3 - methyl - 7 - ( 2 - butyn - 1 - yl ) - 8 - bromoxanthine
CAS No . : 853029-57-9
Synonym : 8 - Bromo - 7 - ( 2 - butyn - 1 - yl ) - 3 , 7 - dihydro - 3 - methyl - 1 - [ ( 4 - methyl - 2 - quinazolinyl ) methyl ] - 1H - purine - 2 , 6 - dione
Molecular Formula : C20H17BrN6O2
Molecular Weight : 453.29
Usage : Linagliptin Intermediate
Description: Linagliptin is the active pharmaceutical ingredient (API) of branded drug Tradjenta, Trajenta or Trazenta. It was innovated by the Germany drug maker Boehringer Ingelheim and cooperated the marketing with Lily. Linagliptin was approve by the US FDA in 2011. Linagliptin is used for the treatment of type 2 diabetes. Linagliptinis is a Dipeptidyl peptidase-4 inhibitor (DPP-4, DPP-IV).
1 - [ ( 4 - Methylquinazolin - 2 - yl ) methyl ] - 3 - methyl - 7 - ( 2 - butyn - 1 - yl ) - 8 - bromoxanthine CAS No . : 853029-57-9 is one of its intermediates. There are several synthesis routes to manufacture this intermediate but some routes are protected by the patents in some countries including Europe, USA and China. We strictly obey the laws and our products are for R&D purpose. But anyway, the buyers should know the patent status by themselves. We promise to supply the real route of synthesis to the buyers. The buyers should take the risks of patent infringement by themselves.
Competitive Advantage: Produced under cGMP conditions, support customers’ registrations.